These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 17576983)

  • 21. We need Romanow's National Drug Agency.
    CMAJ; 2003 Feb; 168(3):249, 251. PubMed ID: 12566321
    [No Abstract]   [Full Text] [Related]  

  • 22. The sustainability of Canada's healthcare system: a framework for advancing the debate. Commentary.
    Lewis S
    Healthc Q; 2007; 10(2):103-4; author reply 105-6. PubMed ID: 18271107
    [No Abstract]   [Full Text] [Related]  

  • 23. Ayerst shutdown demonstrates some patent problems with compulsory licensing.
    Garner J
    Can Pharm J; 1982 Dec; 115(12):450-2. PubMed ID: 10257839
    [No Abstract]   [Full Text] [Related]  

  • 24. Health Canada proposes new regulatory regime for drugs.
    Kondro W
    CMAJ; 2007 Apr; 176(9):1261-2. PubMed ID: 17452653
    [No Abstract]   [Full Text] [Related]  

  • 25. [Monitoring cosmetic product safety].
    Vigan M
    Ann Dermatol Venereol; 2007 Mar; 134(3 Pt 2):2S55-8. PubMed ID: 17563716
    [No Abstract]   [Full Text] [Related]  

  • 26. Fenoterol and death from severe asthma.
    N Z Med J; 1989 Jul; 102(872):389-90. PubMed ID: 2590313
    [No Abstract]   [Full Text] [Related]  

  • 27. [Current status of cosmetic product regulation].
    Pochet A
    Ann Dermatol Venereol; 2007 Mar; 134(3 Pt 2):2S46-54. PubMed ID: 17563715
    [No Abstract]   [Full Text] [Related]  

  • 28. Physicians want transparency as Guidant lawsuits grow.
    Eggertson L
    CMAJ; 2005 Oct; 173(8):855-6. PubMed ID: 16217099
    [No Abstract]   [Full Text] [Related]  

  • 29. Health Canada's investment in new post-market drug surveillance network a "pittance".
    Silversides A
    CMAJ; 2008 Aug; 179(5):412-3. PubMed ID: 18635604
    [No Abstract]   [Full Text] [Related]  

  • 30. Regulatory advice on evaluation of the proarrhythmic potential of drugs.
    Stockbridge N; Throckmorton DC
    J Electrocardiol; 2004; 37 Suppl():40-1. PubMed ID: 15534791
    [No Abstract]   [Full Text] [Related]  

  • 31. Canada's new guidelines for the economic evaluation of pharmaceuticals.
    Menon D; Schubert F; Torrance GW
    Med Care; 1996 Dec; 34(12 Suppl):DS77-86. PubMed ID: 8969316
    [No Abstract]   [Full Text] [Related]  

  • 32. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postmarketing drug surveillance: what it would take to make it work.
    CMAJ; 2001 Nov; 165(10):1293, 1295. PubMed ID: 11760966
    [No Abstract]   [Full Text] [Related]  

  • 34. Canada's fevered failure on malaria.
    Attaran A
    CMAJ; 2007 Apr; 176(9):1249, 1251. PubMed ID: 17452652
    [No Abstract]   [Full Text] [Related]  

  • 35. CANADA'S NEW DRUG REGULATIONS.
    WARNER P; GLASSCO A; KROEKER J
    Can Med Assoc J; 1964 Feb; 90(8):540-1. PubMed ID: 14118696
    [No Abstract]   [Full Text] [Related]  

  • 36. Recommendations regarding technical standards for follow-on biologics: comparability, similarity, interchangeability.
    Davis GC; Beals JM; Johnson C; Mayer MH; Meiklejohn BI; Mitlak BH; Roth JL; Towns JK; Veenhuizen M
    Curr Med Res Opin; 2009 Jul; 25(7):1655-61. PubMed ID: 19476407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Policy and procedure on storage and issuing of drugs for investigational purposes.
    Hays DP
    Hosp Pharm; 1989 Jan; 24(1):47-8. PubMed ID: 10291602
    [No Abstract]   [Full Text] [Related]  

  • 38. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse.
    Butler SF; Budman SH; Licari A; Cassidy TA; Lioy K; Dickinson J; Brownstein JS; Benneyan JC; Green TC; Katz N
    Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1142-54. PubMed ID: 18932173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A current problem: health safety].
    Kossanyi PC
    Rev Infirm; 1998 Oct; (42):59-63. PubMed ID: 9847846
    [No Abstract]   [Full Text] [Related]  

  • 40. Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals.
    Carleton B; Poole R; Smith M; Leeder J; Ghannadan R; Ross C; Phillips M; Hayden M
    Pharmacoepidemiol Drug Saf; 2009 Aug; 18(8):713-21. PubMed ID: 19507171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.